Company · GEHC
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
GE HealthCare expanded adjusted EBIT margin 180bp and free cash flow to $793M, but both profit and cash included a favorable $55M tariff refund.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| GEHC organic revenue | LONG | — | — | — | — | |
| ABBV AbbVie | LONG | +10.3% | — | raised | Oct 30, 2026 | Compare |
| ABT comparable sales growth | LONG | +14.5% | — | maintained | Oct 21, 2026 | Compare |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
